

# A FOCUS ON LUNG CANCERS

THURSDAY, APRIL 6, 2023 | 12–4 P.M. PDT | SAN DIEGO & VIRTUAL



GET THE LATEST IMMUNO-ONCOLOGY EDUCATION ON LUNG CANCERS



**FREE for healthcare professionals, students, patients and patient advocates,** the Advances in Cancer Immunotherapy™ (ACI) programs are CME-, CNE-, CPE- and MOC-certified programs presented by leading authorities in tumor immunology and cancer immunotherapy. This program will present the latest updates in immunotherapy for lung cancers, giving a deep dive into practical application, immune-related adverse events, and future trends.

SCAN TO REGISTER & LEARN MORE



## PROGRAM HIGHLIGHTS

- Overview of common approaches to cancer immunotherapy and their related mechanisms
- Timely updates on the latest clinical advances in the field, including data from recent scientific meetings and clinical trials
- Dedicated opportunities for clinicians to ask questions and receive direction on difficult cases
- Strategies for addressing the practical barriers to implementing immunotherapy (operations, reimbursement and management of emerging toxicities)

## ACCREDITATION INFORMATION

**AMA Credit Designation:** This activity has been approved for *AMA PRA Category 1 Credit(s)*™.

**Pharmacist Credit Designation:** This activity is eligible for ACPE credit, see final CPE activity announcement for specific details.

**Nursing Credit Designation:** This activity is eligible for ANCC contact hours, see final CNE activity announcement for specific details.

**For full accreditation information and to register, please visit [sitcancer.org/lung-cancer](https://sitcancer.org/lung-cancer)**

## ORGANIZERS:



**Kasey Bamel, DNP**

University of California San Diego  
Moore's Cancer Center



**Christopher Coyne, MD, MPH**

University of California  
San Diego Health



**Misako Nagasaka, MD, PhD**

UCI Irvine



**Sandip P. Patel, MD**

University of California San Diego  
Moore's Cancer Center

The 2023 ACI series is jointly provided by the Partners for Advancing Clinical Education and the Society for Immunotherapy of Cancer in collaboration with the Association of Community Cancer Centers, the Advanced Practitioner Society for Hematology and Oncology and the Hematology/Oncology Pharmacy Association.